OPNT [NASD]
Opiant Pharmaceuticals, Inc.
Index- P/E27.65 EPS (ttm)0.45 Insider Own4.30% Shs Outstand4.60M Perf Week-34.98%
Market Cap51.50M Forward P/E- EPS next Y-1.67 Insider Trans-2.94% Shs Float4.36M Perf Month-43.34%
Income3.00M PEG- EPS next Q-1.18 Inst Own33.10% Short Float1.52% Perf Quarter-56.60%
Sales47.80M P/S1.08 EPS this Y-120.20% Inst Trans9.71% Short Ratio0.63 Perf Half Y-56.12%
Book/sh9.13 P/B1.37 EPS next Y-955.80% ROA-1.80% Target Price40.25 Perf Year2.64%
Cash/sh12.18 P/C1.02 EPS next 5Y- ROE-3.00% 52W Range7.34 - 37.71 Perf YTD-62.92%
Dividend- P/FCF- EPS past 5Y36.00% ROI-3.30% 52W High-65.37% Beta0.86
Dividend %- Quick Ratio9.20 Sales past 5Y24.50% Gross Margin81.00% 52W Low77.93% ATR2.55
Employees30 Current Ratio9.20 Sales Q/Q273.60% Oper. Margin-0.70% RSI (14)34.51 Volatility34.74% 16.15%
OptionableNo Debt/Eq0.45 EPS Q/Q126.40% Profit Margin-2.30% Rel Volume1.33 Prev Close12.47
ShortableYes LT Debt/Eq0.45 EarningsMay 10 AMC Payout- Avg Volume106.11K Price13.06
Recom1.70 SMA20-30.06% SMA50-38.48% SMA200-46.02% Volume88,116 Change4.73%
Dec-09-21Initiated Oppenheimer Outperform $42
May-29-19Initiated Northland Capital Outperform
May-12-22 07:20AM  
May-10-22 04:01PM  
May-09-22 10:54AM  
May-03-22 08:00AM  
Apr-29-22 12:47PM  
09:56AM  
Apr-27-22 04:01PM  
Apr-25-22 04:46PM  
Apr-21-22 01:00PM  
Mar-17-22 11:20AM  
Mar-15-22 04:05PM  
Mar-10-22 04:01PM  
Mar-07-22 04:05PM  
Mar-06-22 06:43AM  
Feb-10-22 12:54PM  
08:00AM  
Jan-25-22 07:05AM  
Jan-24-22 04:05PM  
Jan-21-22 05:56AM  
Jan-20-22 05:48PM  
05:45PM  
04:05PM  
Jan-04-22 07:53AM  
Dec-20-21 04:05PM  
Nov-15-21 08:59AM  
Nov-11-21 04:05PM  
Nov-10-21 04:05PM  
Nov-05-21 11:54AM  
Nov-04-21 04:05PM  
Nov-02-21 04:05PM  
Oct-21-21 04:05PM  
Sep-16-21 09:15AM  
Aug-25-21 04:05PM  
Aug-07-21 04:05AM  
Aug-06-21 07:39AM  
Aug-05-21 04:01PM  
Aug-04-21 09:34AM  
Jul-22-21 04:05PM  
Jul-20-21 04:05PM  
Jul-13-21 12:32PM  
Jul-12-21 08:00AM  
Jul-07-21 11:01AM  
07:52AM  
Jul-06-21 04:01PM  
Jun-04-21 06:06AM  
May-24-21 04:05PM  
May-18-21 04:05PM  
May-13-21 07:46AM  
May-11-21 04:05PM  
02:30PM  
May-03-21 04:01PM  
Apr-05-21 04:01PM  
Mar-31-21 04:01PM  
Mar-22-21 04:01PM  
Mar-09-21 06:25AM  
Mar-06-21 02:11AM  
Mar-04-21 04:48PM  
04:05PM  
02:30PM  
08:12AM  
Feb-22-21 04:01PM  
02:44AM  
Feb-12-21 07:15AM  
Feb-09-21 11:30AM  
Feb-08-21 04:01PM  
Dec-15-20 07:52AM  
Dec-14-20 04:01PM  
Dec-10-20 04:01PM  
Dec-07-20 04:01PM  
Nov-27-20 09:58AM  
Nov-17-20 06:16AM  
Nov-12-20 04:41PM  
04:05PM  
02:30PM  
Nov-02-20 04:01PM  
10:11AM  
Oct-29-20 04:05PM  
Oct-27-20 04:01PM  
Sep-21-20 09:56AM  
Sep-14-20 09:46AM  
Aug-31-20 04:05PM  
Aug-24-20 03:50PM  
Aug-17-20 11:46AM  
Aug-10-20 07:45AM  
Aug-06-20 04:05PM  
Jul-23-20 04:01PM  
Jun-30-20 07:08PM  
Jun-08-20 04:14PM  
Jun-07-20 03:36AM  
Jun-05-20 09:37PM  
Jun-04-20 06:40PM  
May-26-20 04:05PM  
May-25-20 12:59PM  
May-21-20 04:05PM  
May-15-20 06:06AM  
May-12-20 04:05PM  
Apr-28-20 08:00AM  
Mar-26-20 02:57PM  
Mar-25-20 11:09PM  
Mar-09-20 07:15AM  
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Skolnick PhilChief Scientific OfficerJan 27Sale26.191,51839,75622,445Jan 27 04:05 PM
CRYSTAL ROGERChief Executive OfficerJan 27Sale26.151,99552,16978,488Jan 27 04:03 PM
O'Toole David DChief Financial OfficerJan 10Sale30.6043213,21935,583Jan 12 04:39 PM
Skolnick PhilChief Scientific OfficerJan 10Sale30.4938511,73923,963Jan 12 04:37 PM
CRYSTAL ROGERChief Executive OfficerJan 10Sale30.491,05832,25880,483Jan 12 04:29 PM
Thomas Thomas T.DirectorSep 22Option Exercise10.001,83418,34011,110Sep 23 04:05 PM
Thomas Thomas T.DirectorSep 22Sale25.0273518,39010,375Sep 23 04:05 PM
Thomas Thomas T.DirectorSep 21Option Exercise10.002,00020,00010,107Sep 23 04:05 PM
Thomas Thomas T.DirectorSep 21Sale24.1283120,0419,276Sep 23 04:05 PM
CRYSTAL ROGERChief Executive OfficerSep 16Buy23.441002,3445,100Sep 16 04:12 PM
Thomas Thomas T.DirectorSep 14Option Exercise10.003,02530,2508,871Sep 16 04:14 PM
Gorman BrianGeneral CounselSep 14Buy19.041,31224,98021,586Sep 14 04:01 PM
O'Toole David DChief Financial OfficerSep 14Buy19.122003,82424,015Sep 15 04:02 PM
Thomas Thomas T.DirectorSep 14Sale19.371,57130,4316,663Sep 16 04:14 PM
Collard Craig ADirectorSep 13Buy18.132,50045,32516,077Sep 15 04:01 PM
Collard Craig ADirectorSep 10Buy18.189,577174,11013,577Sep 13 04:08 PM
Thomas Thomas T.DirectorSep 07Option Exercise10.001,47514,7507,475Sep 09 04:02 PM
Thomas Thomas T.DirectorSep 07Sale18.0082214,7966,653Sep 09 04:02 PM
Ruth Matthew R.Chief Commercial OfficerAug 31Buy17.342,00034,68017,000Sep 01 04:04 PM
Sinclair MichaelDirectorAug 25Option Exercise5.0050,269251,345194,339Aug 25 04:38 PM
Sinclair MichaelDirectorAug 25Sale14.6950,269738,452144,070Aug 25 04:38 PM
Sinclair MichaelDirectorAug 24Option Exercise5.0034,607173,035178,677Aug 25 04:38 PM
Sinclair MichaelDirectorAug 24Sale15.7134,607543,676144,070Aug 25 04:38 PM
Sinclair MichaelDirectorAug 23Option Exercise5.0065,124325,620209,194Aug 25 04:38 PM
Sinclair MichaelDirectorAug 23Sale16.5065,1241,074,546144,070Aug 25 04:38 PM
Thomas Thomas T.DirectorAug 19Sale16.221,00016,2206,000Aug 20 04:04 PM
O'Toole David DChief Financial OfficerAug 16Buy15.386009,22823,815Aug 16 04:47 PM